DIAGONAL BIO AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0298 SEK | -3.56% |
|
-4.18% | -91.56% |
| 05-31 | Diagonal Bio AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 05-23 | Diagonal Bio AB Appoints Fata Mrsic as Chief Financial Officer, Effective June 14, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 81.97 | 10.06 | 14.11 |
| Enterprise Value (EV) 1 | 61.21 | -3.521 | 11.14 |
| P/E ratio | -5.28 x | -0.65 x | -1.1 x |
| Yield | - | - | - |
| Capitalization / Revenue | 9.45 x | 2.72 x | 4.48 x |
| EV / Revenue | 7.06 x | -0.95 x | 3.54 x |
| EV / EBITDA | - | - | -963,287 x |
| EV / FCF | -4,036,438 x | 240,103 x | -1,397,475 x |
| FCF Yield | -0% | 0% | -0% |
| Price to Book | 2.42 x | 1.22 x | 0.66 x |
| Nbr of stocks (in thousands) | 9,149 | 9,149 | 39,976 |
| Reference price 2 | 8.960 | 1.100 | 0.3530 |
| Announcement Date | 4/20/22 | 4/6/23 | 5/15/24 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales 1 | 7.997 | 8.67 | 3.706 | 3.151 |
| EBITDA | - | - | - | -11.56 |
| EBIT 1 | -0.7773 | -11.66 | -15.16 | -11.57 |
| Operating Margin | -9.72% | -134.52% | -409.15% | -367.09% |
| Earnings before Tax (EBT) 1 | -0.7773 | -11.66 | -16.16 | -11.68 |
| Net income 1 | -0.7773 | -11.66 | -16.16 | -11.68 |
| Net margin | -9.72% | -134.52% | -436.16% | -370.61% |
| EPS 2 | -0.2221 | -1.696 | -1.702 | -0.3201 |
| Free Cash Flow | - | -15.16 | -14.67 | -7.971 |
| FCF margin | - | -174.89% | -395.75% | -252.97% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 4/20/22 | 4/20/22 | 4/6/23 | 5/15/24 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | 3.67 | 20.8 | 13.6 | 2.97 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | -15.2 | -14.7 | -7.97 |
| ROE (net income / shareholders' equity) | - | -54.6% | -49.6% | -44.5% |
| ROA (Net income/ Total Assets) | - | -31.7% | -27.1% | -23.1% |
| Assets 1 | - | 36.78 | 59.73 | 50.51 |
| Book Value Per Share 2 | 4.140 | 3.700 | 0.9000 | 0.5300 |
| Cash Flow per Share 2 | 1.710 | 2.270 | 0.3900 | 0.0700 |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 4/20/22 | 4/20/22 | 4/6/23 | 5/15/24 |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -91.56% | 1.17M | |
| +34.14% | 51.12B | |
| -6.54% | 39.4B | |
| +36.02% | 38.48B | |
| +12.62% | 26.36B | |
| -12.11% | 26.22B | |
| -13.43% | 20.96B | |
| +43.73% | 14.02B | |
| +31.81% | 12.49B | |
| -4.54% | 11.61B |
- Stock Market
- Equities
- DIABIO Stock
- Financials Diagonal Bio AB
